Wan Cheng Chow

Dr. Wan Cheng Chow

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Gastroenterology
Verified
Journal Article
Open access
ATAnthony Tanoto Tan
Anthony Tanoto Tan
NYNinghan Yang
Ninghan Yang
TKThinesh Lee Krishnamoorthy
Thinesh Lee Krishnamoorthy
VOVincent Oei
Vincent Oei
ACAlicia Chua
Alicia Chua
ABAntonio Bertoletti
Antonio Bertoletti
Hepatocellular carcinoma (HCC) is often associated with hepatitis B virus (HBV) infection. Cells of most HBV-related HCCs contain HBV-DNA fragments that do not encode entire HBV antigens. We investigated whether these integrated HBV-DNA fragments encode epitopes that are recognized by T cells and whether their presence in HCCs can be used to select HBV-specific T-cell receptors (TCRs) for immunotherapy. HCC cells negative for HBV antigens, based on immunohistochemistry, were analyzed for the presence of HBV messenger RNAs (mRNAs) by real-time polymerase chain reaction, sequencing, and Nanostring approaches. We tested the ability of HBV mRNA-positive HCC cells to generate epitopes that are recognized by T cells using HBV-specific T cells and TCR-like antibodies. We then analyzed HBV gene expression profiles of primary HCCs and metastases from 2 patients with HCC recurrence after liver transplantation. Using the HBV-transcript profiles, we selected, from a library of TCRs previously characterized from patients with self-limited HBV infection, the TCR specific for the HBV epitope encoded by the detected HBV mRNA. Autologous T cells were engineered to express the selected TCRs, through electroporation of mRNA into cells, and these TCR T cells were adoptively transferred to the patients in increasing numbers (1 × 104-10 × 106 TCR+ T cells/kg) weekly for 112 days or 1 year. We monitored patients' liver function, serum levels of cytokines, and standard blood parameters. Antitumor efficacy was assessed based on serum levels of alpha fetoprotein and computed tomography of metastases. HCC cells that did not express whole HBV antigens contained short HBV mRNAs, which encode epitopes that are recognized by and activate HBV-specific T cells. Autologous T cells engineered to express TCRs specific for epitopes expressed from HBV-DNA in patients' metastases were given to 2 patients without notable adverse events. The cells did not affect liver function over a 1-year period. In 1 patient, 5 of 6 pulmonary metastases decreased in volume during the 1-year period of T-cell administration. HCC cells contain short segments of integrated HBV-DNA that encodes epitopes that are recognized by and activate T cells. HBV transcriptomes of these cells could be used to engineer T cells for personalized immunotherapy. This approach might be used to treat a wider population of patients with HBV-associated HCC.

11 May 2021 in Gut
Verified
Journal Article
Open access
PDF file
JLJonathan Wei Jie Lee
Jonathan Wei Jie Lee
FZFeng Zhu
Feng Zhu
SSSupriya Srivastava
Supriya Srivastava
STStephen Kk Tsao
Stephen Kk Tsao
CKChristopher Khor
Christopher Khor
KYKhay-Guan Yeoh
Khay-Guan Yeoh
Objective: To investigate the incidence of gastric cancer (GC) attributed to gastric intestinal metaplasia (IM), and validate the Operative Link on Gastric Intestinal Metaplasia (OLGIM) for targeted endoscopic surveillance in regions with low-intermediate incidence of GC. Methods: A prospective, longitudinal and multicentre study was carried out in Singapore. The study participants comprised 2980 patients undergoing screening gastroscopy with standardised gastric mucosal sampling, from January 2004 and December 2010, with scheduled surveillance endoscopies at year 3 and 5. Participants were also matched against the National Registry of Diseases Office for missed diagnoses of early gastric neoplasia (EGN). Results: There were 21 participants diagnosed with EGN. IM was a significant risk factor for EGN (adjusted-HR 5.36; 95% CI 1.51 to 19.0; p<0.01). The age-adjusted EGN incidence rates for patients with and without IM were 133.9 and 12.5 per 100 000 person-years. Participants with OLGIM stages III–IV were at greatest risk (adjusted-HR 20.7; 95% CI 5.04 to 85.6; p<0.01). More than half of the EGNs (n=4/7) attributed to baseline OLGIM III–IV developed within 2 years (range: 12.7–44.8 months). Serum trefoil factor 3 distinguishes (Area Under the Receiver Operating Characteristics 0.749) patients with OLGIM III–IV if they are negative for H. pylori. Participants with OLGIM II were also at significant risk of EGN (adjusted-HR 7.34; 95% CI 1.60 to 33.7; p=0.02). A significant smoking history further increases the risk of EGN among patients with OLGIM stages II–IV. Conclusions: We suggest a risk-stratified approach and recommend that high-risk patients (OLGIM III–IV) have endoscopic surveillance in 2 years, intermediate-risk patients (OLGIM II) in 5 years.

1 January 2014 in Journal of Hepatology
Verified
Journal Article
Closed access
ATAnthony T. Tan
Anthony T. Tan
LHLong Truong Hoang
Long Truong Hoang
DCDaniel Jie Yuan Chin
Daniel Jie Yuan Chin
ERErik Rasmussen
Erik Rasmussen
ULUri Lopatin
Uri Lopatin
MHMartin Hibberd
Martin Hibberd

18 July 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
WWWho-Whong Wang
Who-Whong Wang
SASoo Fan Ang
Soo Fan Ang
RKRajneesh Kumar
Rajneesh Kumar
CHCharmain Heah
Charmain Heah
AUAndi Utama
Andi Utama
HTHan Chong Toh
Han Chong Toh
Early diagnosis of hepatocellullar carcinoma (HCC) remains a challenge. The current practice of serum alpha-fetoprotein (AFP) measurement is inadequate. Here we utilized a proteomic approach to identify novel serum biomarkers for distinguishing HCC patients from non-cancer controls. We profiled the serum proteins in a group of 58 resectable HCC patients and 11 non-HCC chronic hepatitis B (HBV) carrier samples from the Singapore General Hospital (SGH) using the RayBio® L-Series 507 Antibody Array and found 113 serum markers that were significantly modulated between HCC and control groups. Selected potential biomarkers from this list were quantified using a multiplex sandwich enzyme-linked immunosorbent assay (ELISA) array in an expanded SGH cohort (126 resectable HCC patients and 115 non-HCC chronic HBV carriers (NC group)), confirming that serum prolactin and monocyte chemoattractant protein-1 (MCP-1) were significantly upregulated in HCC patients. This finding of serum MCP-1 elevation in HCC patients was validated in a separate cohort of serum samples from the Mochtar Riady Institute for Nanotechnology, Indonesia (98 resectable HCC, 101 chronic hepatitis B patients and 100 asymptomatic HBV/HCV carriers) by sandwich ELISA. MCP-1 and prolactin levels were found to correlate with AFP, while MCP-1 also correlated with disease stage. Subsequent receiver operating characteristic (ROC) analysis of AFP, prolactin and MCP-1 in the SGH cohort and comparing their area under the ROC curve (AUC) indicated that neither prolactin nor MCP-1 on their own performed better than AFP. However, the combination of AFP+MCP-1 (AUC, 0.974) had significantly superior discriminative ability than AFP alone (AUC, 0.942; p<0.001). In conclusion, prolactin and MCP-1 are overexpressed in HCC and are conveniently quantifiable in patients’ sera by ELISA. MCP-1 appears to be a promising complementary biomarker for HCC diagnosis and this MCP-1+AFP model should be further evaluated as potential biomarker on a larger scale in patients at-risk of HCC.

21 October 2024 in Viruses
Verified
Journal Article
Open access
PDF file
VCVivian Chih-Wei Chen
Vivian Chih-Wei Chen
CJCraig Ryan Joseph
Craig Ryan Joseph
WCWharton O.Y. Chan
Wharton O.Y. Chan
WSWan Rong Sia
Wan Rong Sia
QSQi Su
Qi Su
WCWan Cheng Chow
Wan Cheng Chow
Inflammasome is linked to many inflammatory diseases, including COVID-19 and autoimmune liver diseases. While severe COVID-19 was reported to exacerbate liver failure, we report a fatal acute-on-chronic liver failure (ACLF) in a stable primary biliary cholangitis-autoimmune hepatitis overlap syndrome patient triggered by a mild COVID-19 infection. Postmortem liver biopsy showed sparse SARS-CoV-2-infected macrophages with extensive ASC (apoptosis-associated speck-like protein containing a CARD) speck-positive hepatocytes, correlating with elevated circulating ASC specks and inflammatory cytokines, and depleted blood monocyte subsets, indicating widespread liver inflammasome activation. This first report of a fatal inflammatory cascade in an autoimmune liver disease triggered by a mild remote viral infection hopes to elucidate a less-described pathophysiology of ACLF that could prompt consideration of new diagnostic and therapeutic options.

15 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
NBNina Le Bert
Nina Le Bert
AKApostolos Koffas
Apostolos Koffas
RKRajneesh Kumar
Rajneesh Kumar
FFFloriana Facchetti
Floriana Facchetti
ATAnthony T Tan
Anthony T Tan
PKPatrick Tf Kennedy
Patrick Tf Kennedy
Background & Aims Virus-specific T cells are crucial for controlling viral replication and disease progression in chronic hepatitis B (CHB). Nevertheless, due to the complexity of their analysis, CHB management relies exclusively on virological and biochemical markers. We aimed to develop a point-of-care immunological test, the HBV-cytokine release assay (HBV-CRA), designed to measure multiple cytokines in whole blood after HBV-peptide pool stimulation. Methods We first assessed the assay’s sensitivity by spiking whole blood with engineered HBV-specific T cells. Next, the performance of HBV-CRA was compared to ex vivo IFN-γ ELISpot assays in terms of sensitivity and consistency. We then applied the assay in a cross-sectional study of 235 CHB patients and longitudinally in acute HBV patients during HBsAg sero-clearance. Results The HBV-CRA detected cytokine secretion in response to peptide pools in approximately 80% of CHB patients. A profile of high IL-2 and IFN-γ after Core peptide stimulation was significantly associated with HBsAg clearance in acute HBV. The assay also revealed variability in cytokine levels and responses to different HBV proteins, even within the same clinical phase of CHB. Unsupervised clustering identified distinct HBV-specific immune patterns that did not segregate by clinical and virological categories. Notably, the assay revealed that NUC treatment impacted the functional profile of HBV-specific T cell responses. Conclusions The HBV-CRA is a rapid, easy-to-use assay that detects immune profiles linked to HBsAg clearance and distinguishes CHB patients based on antiviral T cell function. This capability to stratify patients within similar clinical phases offers a novel biomarker for host-viral interactions and could guide the selection of novel immunotherapies.